Clinical trials: System Lupus Erythematosus
Lupus Erythematosus, Systemic
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in approximately 195 participants.
- Trial name
- RECAST SLE (NCT04925934)
- Testing
- VIB7734
- Where
- 67 sites in United States, Argentina and 9 more
- Volunteers
- 214 people
- Sponsor
- Amgen
Lupus Erythematosus, Systemic
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
The purpose of this study is to evaluate the long-term safety of anifrolumab (MEDI-546) in adults with moderate to severe active systemic lupus erythematosus (SLE).
- Trial name
- NCT01753193
- Testing
- Anifrolumab
- Where
- 57 sites in United States, Brazil and 11 more
- Volunteers
- 218 people
- Sponsor
- MedImmune LLC
Systemic Lupus Erythematosus
Web-based Genetic Research on Lupus
The goal of this new lupus research study is two-fold: first, to understand the genetic associations found between people's DNA and this disease, and second, to apply this understanding to drug development efforts with the…
- Trial name
- NCT02530944
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- 23andMe, Inc.
Systemic Lupus Erythematosus
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
- Trial name
- NCT03845517
- Testing
- PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg
- Where
- 164 sites in United States, Argentina and 24 more
- Volunteers
- 350 people
- Sponsor
- Pfizer
Lupus Nephritis
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
The purpose of this study was to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
- Trial name
- NCT05781750
- Testing
- zetomipzomib
- Where
- 50 sites in United States, Argentina and 10 more
- Volunteers
- 84 people
- Sponsor
- Kezar Life Sciences, Inc.
Systemic Lupus Erythematosus
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus…
- Trial name
- GALACELA (NCT05856448)
- Testing
- GLPG3667
- Where
- 84 sites in United States, Argentina and 10 more
- Volunteers
- 186 people
- Sponsor
- Lakefront Biotherapeutics NV
Systemic Lupus Erythematosus
A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)
The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.
- Trial name
- NCT03556007
- Testing
- LY3471851
- Where
- 14 sites in United States
- Volunteers
- 48 people
- Sponsor
- Nektar Therapeutics
Systemic Lupus Erythematosus
Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease
The primary objective of the study is to assess the safety of epratuzumab in patients with SLE.
- Trial name
- NCT00660881
- Testing
- Epratuzumab
- Where
- 42 sites in United States, Belgium and 9 more
- Volunteers
- 210 people
- Sponsor
- UCB Pharma
Systemic Lupus Erythematosus
PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy, safety and tolerability of three different doses of A-623 administered in addition to standard therapy in subjects with active SLE disease
- Trial name
- PEARL-SC (NCT01162681)
- Testing
- A-623
- Where
- 74 sites in United States, Argentina and 9 more
- Volunteers
- 547 people
- Sponsor
- Anthera Pharmaceuticals
Systemic Lupus Erythematosus (SLE)
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
- Trial name
- NCT02804763
- Testing
- Dapirolizumab pegol (DZP)
- Where
- 71 sites in United States, Bulgaria and 11 more
- Volunteers
- 182 people
- Sponsor
- UCB Biopharma S.P.R.L.
Systemic Lupus Erythematosus
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
A Double-blind, Randomized, Placebo-controlled, Dose-escalation Phase I Study to Assess the Safety and PK/PD of LBL-047 Subcutaneous Injection in Healthy Adults and Patients with Systemic Lupus Erythematosus.
- Trial name
- NCT07323173
- Testing
- LBL-047 for Injection
- Where
- 12 sites in China
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Systemic Lupus Erythematosus
Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
This pooled analysis will assess data from the Phase 3 belimumab registration studies BLISS-52 (aka BEL110752) and BLISS-76 (aka BEL110751). The analysis was pre-planned and agreed prior to the unblinding of either study.
- Trial name
- NCT01914770
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Volunteers
- 1,016 people
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome
- Trial name
- NCT06417398
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Lupus Erythematosus
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
To assess the safety, tolerability and pharmacokinetics of ABT-199 in female subjects with Systemic Lupus Erythematosus.
- Trial name
- NCT01686555
- Testing
- ABT-199
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 97 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator…
- Trial name
- ROSY-S (NCT07691970)
- Testing
- Anifrolumab
- Where
- 153 sites in United States, Argentina and 33 more
- Volunteers
- 1,072 people
- Sponsor
- AstraZeneca
Lupus Nephritis
BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB023 in participants with lupus nephritis (LN).
- Trial name
- NCT01930890
- Testing
- BIIB023, mycophenolate mofetil, oral corticosteroids
- Where
- 33 sites in United States, Argentina and 17 more
- Volunteers
- 87 people
- Sponsor
- Biogen
Lupus Nephritis
Aurinia Early Urinary Protein Reduction Predicts Response
An exploratory study assessing the ability of biomarkers measured at 8 weeks to predict clinical response over 24 and 48 weeks in subjects taking voclosporin 23.7 mg twice daily (BID) in combination with standard of care in…
- Trial name
- AURION (NCT02949973)
- Testing
- voclosporin
- Where
- 2 sites in Malaysia
- Volunteers
- 10 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Lupus Nephritis (LN)
C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease
This multi-center, open-label, Phase 1/2 study aims to evaluate the safety, tolerability, and preliminary efficacy of C-CAR168, an autologous anti-CD20/BCMA CAR-T therapy, in patients with autoimmune diseases refractory to…
- Trial name
- NCT06935474
- Testing
- C-CAR168
- Where
- United States
- Sponsor
- AbelZeta Inc.
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune…
- Conditions
- Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid
- Trial name
- NCT00025818
- Testing
- Ophthalmic Emulsion
- Where
- 17 sites in United States
- Volunteers
- 290 people
- Sponsor
- Allergan
Lupus
To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids
The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).
- Trial name
- NCT00053560
- Testing
- Prasterone (GL701)
- Where
- 26 sites in United States, Mexico
- Volunteers
- 155 people
- Sponsor
- Genelabs Technologies